Evaluating The Overall Potential of Peptide Synthesis
Description
The global peptide synthesis market size is estimated to grow from USD 2.8 billion in 2024 to USD 5.1 billion by 2035, representing a CAGR of 5.5% during the forecast period 2024-2035.
The growing popularity and rising demand for peptide-based drugs, specifically the GLP-1 peptide drugs, have garnered the attention of stakeholders to further invest in research and developments of peptides. Peptides represent one of the fastest growing segments of the pharmaceutical industry. This can be attributed to the rapidly growing pipeline of peptide-based therapeutics, driven by the need for effective and personalized pharmacological interventions. Although peptide-based therapeutics have demonstrated the potential to treat a myriad of disease indications, they are generally associated with high costs of development and complex manufacturing protocols.
This has compelled many in-house peptide developers to outsource various aspect of their operations to contract service providers. The peptide synthesis service providers possess advanced capabilities, well-equipped facilities, expensive infrastructure and dedicated capacities for peptide manufacturing to cater to the requirements of clients. Additionally, the contract manufacturers maintain the quality standard of their production units, saving time for the sponsor company.
It is worth highlighting that there is a significant rise in the interest of stakeholders in peptide synthesis indutry; this can be validated by the increase in partnership activity and clinical studies within this domain. Further, the growing demand for peptides has compelled the players engaged in this domain to expand their existing capacities in order to accommodate the future needs of their clients.
The current market landscape features the presence of over 75 players that claim to be engaged in the peptide synthesis market; of these, most of the peptide synthesis service providers are based in Asia-Pacific (30), followed by those located in Europe (24). It is worth noting that Asia-Pacific has emerged as the hub of peptide synthesis. This can be attributed to the fact that CMO market in Asia-Pacific have skilled labor, including scientists and pharma workers.
As can be observed in the figure, majority of the peptide synthesis companies (88%) claim to offer analytical / process development services for peptide APIs. This is followed by peptide synthesis service providers (83%) offering scale-up services to the peptide therapeutics developers. Notable examples of companies offering analytical / process development services that were established post-2015 include (in alphabetical order) EUROAPI, KriSan Biotech, NSJ Prayog Life Sciences and PeptiStar.
Furthermore, it is worth highlighting that most of the players in this domain (98%) manufacture peptides using chemical synthesis method. Of these, 61 players use solid phase synthesis for manufacturing of peptides, followed by those using liquid phase (80%) and hybrid phase synthesis techniques (31%). It is important to highlight that there are 19 companies that claim to have the required capabilities to manufacture peptides using all three chemical synthesis method; notable examples include (in alphabetical order) AmbioPharm, Biopeptek Pharmaceuticals, CordenPharma and Shilpa Medicare.
During our research, we came across several initiatives, including collaborations and expansions, that have been undertaken by various stakeholders in peptide synthesis domain, during the period 2014-2023 (till October). It is worth noting that over the past few years, an inconsistent trend in partnership activity in this domain has been observed. However, a significant increase has been witnessed in 2023 (till October), wherein 11 agreements were signed in peptide synthesis domain. Notable examples of recent agreements include (in reverse chronological order) those signed between PolyPeptide and Peptide Sciences Laboratory of the University of KwaZulu-Natal (UKZN) (October 2023), AmbioPharm and CombiGene (September 2023) and Otsuka Chemical and Yokogawa Electric (March 2023).
Read more at: https://www.rootsanalysis.com/reports/peptide-therapeutics-manufacturing/305.html
Browse More Related Reports:
https://upuge.com/read-blog/21353_trends-driving-growth-of-antibiotics-market.html
https://keepnitreal.net/blogs/47658/Antibiotics-Market-Top-5-Trends-Driving-Growth-in-the-Market
https://cursosvirtuales.cl/project/antibiotics-market-top-5-trends-driving-growth-in-the-market/
https://pharmatrends.weblogco.com/26653311/top-5-trends-driving-growth-of-antibiotics-industry
https://blogzone.hellobox.co/6740204/top-trends-in-cancer-biomarkers-industry
https://www.aniarticles.com/34686-top-5-trends-driving-growth-in-the-antibiotics-market
https://pharmatrends.pages10.com/remote-patient-monitoring-types-benefits-and-future-trends-62396791
https://havily.com/3d-cell-culture-market-size-share-industry-analysis-report-2035/
https://ecency.com/medical/@rootsanalysis/medical-device-coatings-market-trends
https://feedingtrends.com/what-are-single-use-bioreactors
https://theamberpost.com/post/metabolomics-technological-advancements-and-portfolio
Business Hours
Business Hour
- Monday Closed
- Tuesday Closed
- Wednesday Closed
- Thursday Closed
- Friday Closed
- Saturday Closed
- Sunday Closed
Location
